Back to top
more

Verve Therapeutics (VERV)

(Delayed Data from NSDQ)

$6.28 USD

6.28
1,729,594

+0.61 (10.76%)

Updated Jul 9, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (154 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Verve Therapeutics (VERV) delivered earnings and revenue surprises of 13.24% and 12.77%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Biotech Stock Roundup: IRON, VERV Down on Study Updates, BMYs Drug News & More

by Zacks Equity Research

Disc Medicine, Inc. (IRON) and Verve Therapeutics (VERV) fall on study updates.

Verve (VERV) Pauses Enrollment in Cholesterol Study, Stock Falls

by Zacks Equity Research

Verve (VERV) stops enrollment in the phase Ib study of gene therapy candidate VERVE-10 to reduce disease-driving low-density lipoprotein cholesterol due to safety issues. Stock plunges on the news.

Relay Therapeutics, Inc. (RLAY) Moves 10.0% Higher: Will This Strength Last?

by Zacks Equity Research

Relay Therapeutics, Inc. (RLAY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Verve Therapeutics (VERV) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

Verve Therapeutics (VERV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Wall Street Analysts Think Verve Therapeutics (VERV) Could Surge 217.73%: Read This Before Placing a Bet

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 217.7% in Verve Therapeutics (VERV). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Believe Verve Therapeutics (VERV) Could Rally 260.31%: Here's is How to Trade

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 260.3% in Verve Therapeutics (VERV). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Does Verve Therapeutics (VERV) Have the Potential to Rally 260.31% as Wall Street Analysts Expect?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 260.3% in Verve Therapeutics (VERV). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Predict a 160.72% Upside in Verve Therapeutics (VERV): Here's What You Should Know

by Zacks Equity Research

The consensus price target hints at a 160.7% upside potential for Verve Therapeutics (VERV). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Verve Therapeutics (VERV) Surges 28.0%: Is This an Indication of Further Gains?

by Zacks Equity Research

Verve Therapeutics (VERV) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Verve Therapeutics (VERV) Soars 13.8%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Verve Therapeutics (VERV) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Verve Therapeutics (VERV) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Verve Therapeutics (VERV) delivered earnings and revenue surprises of 4.40% and 21.33%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

How Much Upside is Left in Verve Therapeutics (VERV)? Wall Street Analysts Think 93.5%

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 93.5% in Verve Therapeutics (VERV). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Verve (VERV) Up 9.9% in a Week on Collaboration With Eli Lilly

by Zacks Equity Research

Verve's (VERV) shares rise on collaboration with Eli Lilly to develop gene editing treatment for cardiovascular disease.

Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Verve Therapeutics (VERV) delivered earnings and revenue surprises of -7.69% and 40.40%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Biotech Stock Roundup: REGN, AMGN, MRNA's Q3 Earnings, VERV Down on Update

by Zacks Equity Research

Earnings updates from REGN and MRNA are the key highlights from the biotech sector during the past week.

Verve Therapeutics (VERV) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Verve Therapeutics (VERV) delivered earnings and revenue surprises of -5.33% and 81.42%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Biotech Stock Roundup: BMY, BIIB's Q2 Earnings, GILD's Updates & More

by Zacks Equity Research

Earnings updates from Bristol Myers (BMY) and Biogen (BIIB) are a few key highlights from the biotech sector during the past week.

Verve (VERV) Up on Gene Editing Collaboration With Vertex

by Zacks Equity Research

Verve Therapeutics (VERV) enters into a four-year collaboration with Vertex Therapeutics to develop a gene-editing program targeted at liver disease for an upfront payment of $60 million.

    Company News for Mar 15, 2022

    by Zacks Equity Research

    Companies In The News Are: BLDP, GOL, VERV, PFE.

    Indrajit Bandyopadhyay headshot

    3 Synthetic Biology Stocks in Focus With Strong Potential

    by Indrajit Bandyopadhyay

    Here we discuss three stocks - CDXS, PGEN, VERV - engaged in the field of scientific biology that investors may keep a tab of as these have the potential to generate wealth for them going forward.